228760.KQ Genomictree Inc.
- Market cap
- KRW 245B
- P/E
- -
- P/B
- 2.01x
- ROE
- -7.2%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 228760.KQ undervalued?
Graham numberThe Graham number of Genomictree Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genomictree Inc. fundamental analysis
5 of 21 checks passedROE 0/2
Low return on equity (-7.2%), below 10%.
ROA 0/1
Return on assets (-7.0%) is below the industry median (1.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (14.2%) is above the industry median (1.8%).
Revenue Growth 0/2
Revenue shrank 49.9% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 1/2
Cash covers 1.3 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (2.0x) is above the industry median (0.9x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Genomictree Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genomictree Inc.
Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer…
Full company profileGenomictree Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Genomictree Inc. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | 266M | 1.24B | 5.14B | 29.9B | 3.42B | 2.36B | 3.76B | 2.45B |
| Gross Profit | - | -516M | 55.2M | 2.52B | 25.0B | -270M | -727M | 714M | -377M |
| Operating Income | - | -12.3B | -12.4B | -9.86B | 4.28B | -12.7B | -15.3B | -11.3B | -11.3B |
| EBITDA | - | - | - | - | 3.02B | -6.27B | -8.91B | -7.71B | -7.54B |
| Net Income | - | -9.60B | -11.8B | -11.4B | -6.63B | -8.76B | -10.2B | -8.99B | -8.73B |
| EPS | - | - | -590 | -562 | -321 | -371 | -427 | -366 | -356 |
| Balance Sheet | |||||||||
| Total Assets | - | - | 118B | 177B | 163B | 133B | 131B | 121B | 124B |
| Total Liabilities | - | - | 22.6B | 62.1B | 55.9B | 7.81B | 6.36B | 5.45B | 2.48B |
| Shareholders' Equity | - | - | 95.3B | 115B | 107B | 125B | 124B | 115B | 122B |
| Cash & Short-term Investments | - | - | 56.6B | 66.5B | 115B | 86.1B | 96.1B | 16.3B | 17.5B |
| Cash Flow | |||||||||
| Operating Cash Flow | -2.08B | -8.77B | -10.2B | -7.63B | 4.29B | -10.9B | -13.6B | -10.2B | -9.83B |
| Capital Expenditure | 2.69B | 2.24B | 2.68B | 11.8B | 1.82B | 288M | 2.55B | 2.75B | 3.65B |
| Free Cash Flow | - | - | -13.0B | -19.5B | 2.46B | -11.2B | -16.2B | -12.9B | -13.5B |
| Ratios | |||||||||
| ROE | - | - | -12.4% | -9.9% | -6.2% | -7.0% | -8.3% | -7.8% | -7.2% |
| ROA | - | - | -10.0% | -6.4% | -4.1% | -6.6% | -7.8% | -7.4% | -7.0% |
| Net Profit Margin | - | -3,603.6% | -952.1% | -222.3% | -22.2% | -256.2% | -433.6% | -239.0% | -356.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Genomictree Inc. dividends
Genomictree Inc. has not paid dividends in the last 8 fiscal years.
Last stock split: 2:1 on Sep 14, 2018.
Who owns Genomictree Inc.
- Insiders 16.85%
- Institutions 0.56%
- Public & others 82.60%
- Shares outstanding 24.5M
- Free float 20.7M
Genomictree Inc. company profile
- Company name
- Genomictree Inc.
- Ticker
- 228760.KQ
- ISIN
- KR7228760005
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 79
- Fiscal year end
- December
- Address
- 44-6 Techno 10-ro, Daejeon, South Korea, 34027
- Phone
- 82 4 2861 4551
- Website
- genomictree.com
About Genomictree Inc.
Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraDTect SARS-CoV-2 RT-qPCR kits, test providers, and nucleic acid transport medium products. The company was founded in 2000 and is headquartered in Daejeon, South Korea.
Genomictree Inc. management
6- Mr. Chi-Wang YoonCOO & VP · born 1962
- Dr. Sung-Whan AnCEO & President · born 1961
- Hong Sun LeeHead of Management Support Headquarters & CFO
- Dr. Tae-Jeong Oh Ph.D.Head of R&D Division · born 1966
- Un Lee YongHead of Business Division
- Soon Kim MyungHead of Molecular Diagnostic Lab